期刊文献+

成人原发性甲减患者血浆SS、SP含量的变化

Changes of Plasma SS,SP Contents in Adult Patients with Primary Hypothyroidism
下载PDF
导出
摘要 目的:观察成人原发性甲状腺机能减退(甲减)患者甲状腺素(TH)治疗前后脑神经肽变化,以探索甲减致脑中枢神经系统损害的机制。方法:采用放射免疫分析,对比分析了45例成人原发性甲减患者TH治疗前后血浆中生长抑素(SS)、P物质(SP)变化。结果:甲减组血浆中SP水平明显低于正常对照组(P<0.01),SS水平与正常对照组比较无显著性差异(P>0.05),其中FT3≥2.5pmol/L组病人血浆中SS水平与正常对照组比较无显著性差异(P>0.05),FT3<2.5pmol/L组血浆中SS含量低于正常对照组(P<0.05),经过TH治疗后SS、SP水平提高(P<0.05,P<0.01)。结论:成人原发性甲减患者血浆存在不同程度的SS、SP减低,这与其引起的神经精神症状可能密切相关,早期、积极、正规的TH治疗对脑功能的恢复有很重要的意义。 Objective To investigate the possible mechanism of imparirment of central nervous system function in hypothyroid patients through determination of changes of plasma neuropeptides after thyroid hormone replacement therapy. Methods Plasma aomatostatin (SS) and substance P (SP) contents were measured with R/A in 45 patients with primary hypothyroidism both before and after thyroid hormone replacement therapy as well as in 38 controls. Results Before treatment, the plasma contents of SP in the patients were significantly lower than those in the controls (P 〈 0.05 ) but plasma SS contents in the patients were not much different from those in controls (P 〉 0.05). However, the plasma contents of SS in the more advanced hypothyroid patients with FT3 〈 2.5pmol/L (27/45) were significantly lower than those in controls (P 〈 0.05 ). After two months' hormone replacement therapy with normalization of the FT3 , FT4 levels, the plasma SS, SP increased significantly ( vs before treatment P 〈 0.05, P 〈 0.01 ). Conclusion The decrease of plasma contents of SS and SP in patients with hypothyroidism might be related to the development of psycho - neurological symptoms in these patients and thyroid hormone replacement therapy was desirable.
出处 《放射免疫学杂志》 CAS 2008年第2期132-134,共3页 Journal of Radioimmanology
基金 陕西省科技攻关项目[编号:2007K15-01(13)]
关键词 成人 甲状腺机能减退 血浆 生长抑素 P物质 adult, hypothyroidism, blood plasma, somatostatin, substance P
  • 相关文献

参考文献13

  • 1俞淑静,费大东.老年甲状腺功能减退症六例误诊为精神疾病[J].临床误诊误治,1999,12(5):330-331. 被引量:6
  • 2武丽,张丽萍,叶庆莲,蒋应时.加减温胆汤对抑郁模型大鼠行为学和血浆生长抑素含量的影响[J].中国临床康复,2005,9(8):114-115. 被引量:36
  • 3Feyen JH, Elford P, Di Padova FE, et al. Interleukin -6 is produced by bone and tumodulated by parathyroid hormone. J Bone Miner Res. 1989,4(4) :633.
  • 4顾明君,李翔,蔡斌.生长抑素受体与甲状腺眼病[J].第二军医大学学报,2003,24(5):538-539. 被引量:19
  • 5黄伟文.Graves眼病治疗的现状与展望[J].国外医学(内分泌学分册),2001,21(6):317-319. 被引量:6
  • 6Roussel JP, Grazzini E, Astrier H. Somatostatin blocks the potentiation of TRH - induced TSH secrtion from ptuified pituitary fragments pituitary cells elicited by prepro -TRH(PS4) or by triiodothyronine. J Mol Endocrinol. 1997,19 (1) :87.
  • 7Ahren B. Regulatory peptides in the thyroid gland -a review of their localization and function. Acta Endocrinol (Copenh). 1991,124 ( 3 ) : 225.
  • 8De Felipe C, Herrero JF, Bfien JA, et al. Altered nociception,analgesia and aggression in mice lacking the receptor for substance P. Nature. 1998,392 (6674) :394.
  • 9Freund TF, Ylinen A, Miettinen R, et al. Pattern of neuronal death in the rat hippocampus after status epilepticus relationship to calcium binding protein content and ischemic vulnerabilihy. Brain Res. 1992, 8 (1) :27.
  • 10Marangell LB, Ketter TA, George MS, et al. Inverse relationship of peripheral thyrotropin - stimulating hormone levels to brain activity in mood disorders. Am J Psychiatry. 1997,154 (2) :224.

二级参考文献33

  • 1翟双庆,王洪图.论中焦气机与神志关系[J].北京中医药大学学报,1995,18(5):10-11. 被引量:27
  • 2贾少微 潘中允.脑灌注显像[A].见:中华人民共和国卫生部医政司.核医学诊断与治疗规范[M].北京:科学出版社,1997.95-101.
  • 3王永炎.中医内科学[M].上海:上海科技出版社,1998.58—72.
  • 4Kahaly G,Diaz M,Hahn K,et al.Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy[J].J Nucl Med,1995,36(4):550-554.
  • 5Krassas GE,Kahaly GJ.The role of octreoscan in thyroid eye disease[J].Eur J Endocrinol,1999,140(5):373-375.
  • 6Nocaudie M,Bailliez A,Itti E,et al.Somatastatin receptor scintigraphy to predict the clinical evolution and theraputic response of thyroid associated ophthalmopathy[J].Eur J Nucl Med,1999,26(5):511-517.
  • 7Colao A,Lastoria S,Ferone D,et al.Orbital scintigraphy with [111In-diethylenetriamine pantaacetic acid-D-Phe]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy[J].J Clin Endocrinol Metab,1998,83(11):3790-3794.
  • 8Krassas GE,Dumas A,Pontikides N,et al.Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease[J],Clin Endocrinol,1995,42(6):571.
  • 9Gerding MN,van-der-Zant FM,van Royen EA,et al.Octreotide scintigraphy is a disease activity parameter in Graves' ophthalmopathy[J].Clin Endocrinol Oxf,1999,50(3):373-379.
  • 10Perros P,Crombie A L,Kendall-Taylor P.Natural history o f thyroid-associated ophthalmopathy [J].J Clin Endocrinol,1995,42:45-50.

共引文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部